Literature DB >> 14580197

Binding and orientation of conantokins in PL vesicles and aligned PL multilayers.

Qiuyun Dai1, Jaroslav Zajicek, Francis J Castellino, Mary Prorok.   

Abstract

The association of a ligand with its cognate cell surface receptor can be facilitated by interactions between the ligand and the lipid phase of the cell membrane. With respect to the N-methyl-D-aspartate receptor (NMDAR), we have previously established a low affinity, nonreceptor-mediated interaction of the peptidic conantokins with synaptic membranes in conjunction with a high affinity binding to the NMDARs present therein [Klein, R. C., Prorok, M., and Castellino, F. J. (2003) J. Pept. Res. 61, 307-317]. In the current study, several techniques including size-exclusion chromatography, circular dichroism, fluorescence, and NMR spectroscopies were used to investigate the binding, conformation, and orientation of conantokins and their variants to a variety of phospholipid (PL) vesicles and multilayers. We have found that conantokins bind to PLs and that the effectors Ca(2+) and spermine slightly increase this binding ability. The conantokins preserve a high degree of helical conformation when bound to vesicles in the presence of Ca(2+). In the absence of Ca(2+), only conantokin-G (con-G) manifests an increase in conantokin helicity with increasing vesicle concentration. In solution, the conantokins appear to be localized at the headgroup of vesicles and do not insert into the hydrophobic core of the bilayer. On aligned PL films, the helical axis of the conantokins can either reside normal to the membrane surface or partition in a parallel orientation, depending on the nature of the conantokins and the PLs used. These orientation preferences may be conjoined with the biological activities of the conantokins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14580197     DOI: 10.1021/bi034918p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  3 in total

1.  Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.

Authors:  Yuxian He; Jianwei Cheng; Hong Lu; Jingjing Li; Jie Hu; Zhi Qi; Zhonghua Liu; Shibo Jiang; Qiuyun Dai
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

2.  Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.

Authors:  Yuxian He; Jianwei Cheng; Jingjing Li; Zhi Qi; Hong Lu; Mingxin Dong; Shibo Jiang; Qiuyun Dai
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

3.  A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity.

Authors:  Zhuguo Liu; Zheng Yu; Yuanyuan Huang; Yan Zhang; Guozhu Han; Xian Li; Mingxin Dong; Shuo Yu; Yu Wang; Jie Hu; Huiqin Guo; Yuanguo Cheng; Li Lv; Qiuyun Dai
Journal:  Sci Rep       Date:  2015-09-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.